Given the health risks of cancer and cardiovascular events associated with hormone replacement therapy, it is no longer recommended as first-line treatment for women with low bone density.
Ngenxa yomngcipheko womhlaza nezifo zentliziyo ezinxulumene nonyango lokufakelwa kweehomoni olu nyango alusetyenziswa njengonyango lokuqala olunikwa ibhinqa elinobunzima bamathabo obusezantsi.